Connor Clark & Lunn Investment Management Ltd. Buys 295,378 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 71.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 711,278 shares of the biopharmaceutical company’s stock after acquiring an additional 295,378 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Esperion Therapeutics were worth $1,174,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ESPR. Vanguard Group Inc. raised its position in shares of Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after buying an additional 3,688,796 shares in the last quarter. Marshall Wace LLP raised its position in shares of Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 2,087,635 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Esperion Therapeutics by 3,278.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 555,382 shares in the last quarter. Inspire Investing LLC purchased a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at about $758,000. Finally, XTX Topco Ltd raised its position in shares of Esperion Therapeutics by 751.6% during the 2nd quarter. XTX Topco Ltd now owns 364,681 shares of the biopharmaceutical company’s stock valued at $810,000 after buying an additional 321,859 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR opened at $2.54 on Thursday. The company has a market cap of $500.48 million, a P/E ratio of -3.97 and a beta of 0.96. Esperion Therapeutics, Inc. has a 1 year low of $1.16 and a 1 year high of $3.40. The firm has a 50-day simple moving average of $2.08 and a two-hundred day simple moving average of $2.16.

Wall Street Analyst Weigh In

ESPR has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Wednesday. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Needham & Company LLC decreased their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.